- Published on
Infectious Disease and Microbiology – Anthrax
Anthrax is a zoonotic infection primarily affecting herbivorous animals and only occasionally humans. The term derives from the Greek word for coal, referring to the characteristic black eschar seen in cutaneous disease. In humans, anthrax presents in three principal forms: cutaneous, inhalational (respiratory), and gastrointestinal. The incubation period ranges from 3–10 days for cutaneous disease and 3–5 days for pulmonary disease. Although rare in the United States, anthrax has been associated with exposure to contaminated wool, hides, and animal products, as well as foodborne outbreaks from tainted meat. The 2001 bioterrorism-related outbreak in the US resulted in 22 cases, including 11 inhalational cases and 5 deaths. A newer “injectional” form has been described among injection drug users, notably in Scotland, with significant mortality.
The causative agent, Bacillus anthracis, is an aerobic, gram-positive, spore-forming bacillus. Its spores are highly resistant to environmental stressors such as drying, radiation, and disinfectants and can persist in soil for years. Major risk factors in endemic developing regions include contact with contaminated soil or infected animals, while in urban areas exposure to contaminated animal products is more common. Prevention strategies include livestock vaccination, decontamination of animal products, and vaccination of high-risk groups such as military personnel, veterinarians, and individuals handling imported hides.
The pathogenesis of anthrax depends largely on the production of two binary toxins: lethal toxin and edema toxin. These toxins disrupt host immune responses and contribute to tissue necrosis, edema, and systemic toxicity. Clinically, cutaneous anthrax is the most common presentation. It begins as a painless papule that progresses to a vesicle and then to a characteristic black eschar measuring 1–3 cm, surrounded by edema. If untreated, cutaneous infection may progress to bacteremia and sepsis.
Inhalational anthrax often presents in two phases. The initial phase resembles a nonspecific viral upper respiratory illness lasting several days, followed by rapid deterioration with severe pneumonitis, respiratory distress, and systemic toxicity. Mediastinal widening on chest radiograph is a hallmark finding in advanced disease. The combination of mediastinal widening, altered mental status, and elevated hematocrit has been reported as highly sensitive in distinguishing inhalational anthrax from community-acquired pneumonia. Gastrointestinal anthrax presents with abdominal pain, nausea, vomiting, fever, and may include hematemesis or hematochezia. Injectional anthrax, seen in injection drug users, manifests with severe soft tissue infection, marked edema, and may include intracranial hemorrhage or gastrointestinal symptoms. Meningoencephalitis can complicate any form through hematogenous spread and may present with hemorrhagic cerebrospinal fluid and rapid progression to coma.
Diagnosis relies on clinical suspicion and laboratory confirmation. Gram stain and culture of vesicular fluid from cutaneous lesions typically demonstrate large, encapsulated gram-positive rods in short chains. Blood cultures are often positive in systemic disease, and stool cultures may reveal the organism in gastrointestinal infection. Chest imaging may show infiltrates, pleural effusions, and mediastinal widening. Differential diagnosis varies by presentation and includes tularemia, staphylococcal infections, spider bites, burns, bacterial or viral pneumonias, enteric bacterial infections, tuberculosis, and viral or amebic meningoencephalitis.
Treatment depends on disease severity and route of acquisition. Uncomplicated cutaneous anthrax in individuals older than two years can be treated with oral ciprofloxacin or doxycycline for 7–10 days. If susceptibility is confirmed, penicillin or amoxicillin may be used. Severe cutaneous disease requires intravenous therapy. Inhalational, gastrointestinal, or systemic anthrax requires prompt intravenous combination therapy, typically including ciprofloxacin plus one or two additional agents such as a carbapenem, rifampin, vancomycin, penicillin, chloramphenicol, or clindamycin. At least one agent with good central nervous system penetration should be included due to the risk of meningitis. In bioterrorism-related exposure, prolonged therapy for 60 days is recommended. Raxibacumab, a monoclonal antibody targeting anthrax toxin, has shown benefit in animal models of inhalational disease.
Prognosis depends on the form of disease and timeliness of treatment. Cutaneous anthrax generally responds well to therapy but often leaves a residual scar. Inhalational and gastrointestinal forms carry high mortality rates if not treated promptly. Close follow-up is required to monitor for recurrence or complications.
Anthrax is a zoonotic infection primarily affecting herbivorous animals and only occasionally humans. The term derives from the Greek word for coal, referring to the characteristic black eschar seen in cutaneous disease. In humans, anthrax presents in three principal forms: cutaneous, inhalational (respiratory), and gastrointestinal. The incubation period ranges from 3–10 days for cutaneous disease and 3–5 days for pulmonary disease. Although rare in the United States, anthrax has been associated with exposure to contaminated wool, hides, and animal products, as well as foodborne outbreaks from tainted meat. The 2001 bioterrorism-related outbreak in the US resulted in 22 cases, including 11 inhalational cases and 5 deaths. A newer “injectional” form has been described among injection drug users, notably in Scotland, with significant mortality.
The causative agent, Bacillus anthracis, is an aerobic, gram-positive, spore-forming bacillus. Its spores are highly resistant to environmental stressors such as drying, radiation, and disinfectants and can persist in soil for years. Major risk factors in endemic developing regions include contact with contaminated soil or infected animals, while in urban areas exposure to contaminated animal products is more common. Prevention strategies include livestock vaccination, decontamination of animal products, and vaccination of high-risk groups such as military personnel, veterinarians, and individuals handling imported hides.
The pathogenesis of anthrax depends largely on the production of two binary toxins: lethal toxin and edema toxin. These toxins disrupt host immune responses and contribute to tissue necrosis, edema, and systemic toxicity. Clinically, cutaneous anthrax is the most common presentation. It begins as a painless papule that progresses to a vesicle and then to a characteristic black eschar measuring 1–3 cm, surrounded by edema. If untreated, cutaneous infection may progress to bacteremia and sepsis.
Inhalational anthrax often presents in two phases. The initial phase resembles a nonspecific viral upper respiratory illness lasting several days, followed by rapid deterioration with severe pneumonitis, respiratory distress, and systemic toxicity. Mediastinal widening on chest radiograph is a hallmark finding in advanced disease. The combination of mediastinal widening, altered mental status, and elevated hematocrit has been reported as highly sensitive in distinguishing inhalational anthrax from community-acquired pneumonia. Gastrointestinal anthrax presents with abdominal pain, nausea, vomiting, fever, and may include hematemesis or hematochezia. Injectional anthrax, seen in injection drug users, manifests with severe soft tissue infection, marked edema, and may include intracranial hemorrhage or gastrointestinal symptoms. Meningoencephalitis can complicate any form through hematogenous spread and may present with hemorrhagic cerebrospinal fluid and rapid progression to coma.
Diagnosis relies on clinical suspicion and laboratory confirmation. Gram stain and culture of vesicular fluid from cutaneous lesions typically demonstrate large, encapsulated gram-positive rods in short chains. Blood cultures are often positive in systemic disease, and stool cultures may reveal the organism in gastrointestinal infection. Chest imaging may show infiltrates, pleural effusions, and mediastinal widening. Differential diagnosis varies by presentation and includes tularemia, staphylococcal infections, spider bites, burns, bacterial or viral pneumonias, enteric bacterial infections, tuberculosis, and viral or amebic meningoencephalitis.
Treatment depends on disease severity and route of acquisition. Uncomplicated cutaneous anthrax in individuals older than two years can be treated with oral ciprofloxacin or doxycycline for 7–10 days. If susceptibility is confirmed, penicillin or amoxicillin may be used. Severe cutaneous disease requires intravenous therapy. Inhalational, gastrointestinal, or systemic anthrax requires prompt intravenous combination therapy, typically including ciprofloxacin plus one or two additional agents such as a carbapenem, rifampin, vancomycin, penicillin, chloramphenicol, or clindamycin. At least one agent with good central nervous system penetration should be included due to the risk of meningitis. In bioterrorism-related exposure, prolonged therapy for 60 days is recommended. Raxibacumab, a monoclonal antibody targeting anthrax toxin, has shown benefit in animal models of inhalational disease.
Prognosis depends on the form of disease and timeliness of treatment. Cutaneous anthrax generally responds well to therapy but often leaves a residual scar. Inhalational and gastrointestinal forms carry high mortality rates if not treated promptly. Close follow-up is required to monitor for recurrence or complications.
0 Comments
